IL17A and myeloid sarcoma: Thus, despite the increase in IL-17A by IC-mediated type II activation, type II macrophages and type II microglia activated by other type II compounds likely represent a protective subset of cells, which, if induced in vivo may help protect against inflammatory conditions such as MS.